Your browser is no longer supported. Please, upgrade your browser.
Settings
PLSE Pulse Biosciences, Inc. daily Stock Chart
PLSE [NASD]
Pulse Biosciences, Inc.
Index- P/E- EPS (ttm)-0.57 Insider Own1.90% Shs Outstand13.76M Perf Week5.96%
Market Cap200.48M Forward P/E- EPS next Y- Insider Trans26.41% Shs Float8.67M Perf Month139.24%
Income-6.70M PEG- EPS next Q- Inst Own1.60% Short Float1.19% Perf Quarter146.95%
Sales- P/S- EPS this Y-916.50% Inst Trans-12.34% Short Ratio1.56 Perf Half Y211.32%
Book/sh2.09 P/B6.97 EPS next Y- ROA- Target Price- Perf Year-
Cash/sh1.36 P/C10.72 EPS next 5Y- ROE- 52W Range4.03 - 16.01 Perf YTD124.15%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-8.99% Beta-
Dividend %- Quick Ratio19.70 Sales past 5Y- Gross Margin- 52W Low261.54% ATR0.93
Employees11 Current Ratio19.70 Sales Q/Q- Oper. Margin- RSI (14)85.59 Volatility8.74% 8.11%
OptionableNo Debt/Eq0.00 EPS Q/Q-162.70% Profit Margin- Rel Volume2.76 Prev Close14.59
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume66.49K Price14.57
Recom- SMA2047.99% SMA5092.41% SMA200150.53% Volume183,636 Change-0.14%
Feb-23-17 01:11PM  StreetSweeper's New Short: Pulse Biosciences
Feb-22-17 05:31PM  Heres where a Pinellas billionaire and top donor to Church of Scientology is putting his investment dollars at bizjournals.com
Feb-21-17 05:13PM  PULSE BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Feb-10-17 09:24AM  PULSE BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity S +23.84%
08:30AM  Pulse Biosciences Announces Healthcare Executives and Entrepreneurs Robert Duggan and Dr. Maky Zanganeh Have Acquired a Combined Interest of 17.1% of the Company Business Wire
Jan-27-17 03:53PM  PULSE BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
Nov-14-16 04:01PM  PULSE BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition
04:00PM  Pulse Biosciences Quarterly Nano-Pulse Stimulation (NPS) Update Business Wire
08:00AM  Pulse Biosciences Announces First Clinical Use of the Proprietary PulseTx Platform in a Pilot Study in Dermatology Business Wire
Nov-11-16 08:00AM  Pulse Biosciences Announces New Data That Reinforce Potential Immuno-Oncology Benefits of Nano-Pulse Stimulation Technology Business Wire
Nov-02-16 03:00PM  Pulse Biosciences to Host Third Quarter Investor Conference Call on November 14, 2016 Business Wire
Oct-18-16 08:00AM  Pulse Biosciences to Present New Data at the Society for Immunotherapy in Cancer Annual Meeting Business Wire
Pulse Biosciences, Inc., a development stage medical device company, focuses on developing medical technologies based on sub-microsecond pulsed electric field technology to detect and treat skin cancer and enhance wound healing. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was founded in 2014 and is based in Burlingame, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Zanganeh MakyDirectorFeb 15Buy11.9713,000155,64933,474Feb 22 02:48 PM
DUGGAN ROBERT W10% OwnerFeb 09Buy11.6441,624484,5032,173,359Feb 22 02:48 PM